AtezolizumabBevacizumabAtezo/BevHCCFudan Universityhepatocellular carcinomaImmune-checkpoint blockade therapiesZhongshan Hospital
… hepatocellular carcinoma (HCC) exhibiting varying responses to Atezolizumab plus Bevacizumab (Atezo/Bev), and profiled the tumor ecosystems…